Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study.

Cancer science - 1 May 2026

Mizuno Kazuyuki, Ishikawa Takuya, Ito Takanori, Takano Yuko, Maeda Osamu, Kawashima Hiroki, Ando Yuichi

Abstract excerpt

The clinical impact of BRCA2 variants and tumor mutational burden (TMB) on first-line regimen selection-FOLFIRINOX (FFX) versus gemcitabine plus nab-paclitaxel (GnP)-for pancreatic ductal adenocarcinoma (PDAC) remains unclear. Using the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, we analyzed patients with unresectable or recurrent PDAC treated with first-line FFX or GnP. Overall...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albumins
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Gemcitabine

Share to Irinotecan

Share to Leucovorin

Share to Oxaliplatin

Share to Paclitaxel

Source

Open in PubMed Open full text

Identifiers

PMID: 41795872
DOI: 10.1111/cas.70351
PMCID: PMC13134512

Genes

BRCA2
CAT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study.PMID 41795872Read ↗

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean PatientsSemantic proximity Read ↗

Pancreas cancer and BRCA : A critical subset of patients with improving therapeutic outcomesSemantic proximity Read ↗

Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study.Semantic proximity Read ↗

Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications.Semantic proximity Read ↗

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.Semantic proximity Read ↗

Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.Semantic proximity Read ↗

The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of LiteraturesSemantic proximity Read ↗

TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.Semantic proximity Read ↗

Immunotherapy Combined with Chemotherapy versus Chemotherapy Alone in Advanced Pancreatic Ductal Adenocarcinoma: a Real-world Retrospective Cohort StudySemantic proximity Read ↗

Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT databaseSemantic proximity Read ↗

BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.